Vimarsana
Biggest News Aggregation in the World

Cachexia Sarcopenia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cachexia Sarcopenia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cachexia Sarcopenia Today - Breaking & Trending Today

What is The Connection Between Follistatin-344 and Muscle? - Vimarsana News

What is The Connection Between Follistatin-344 and Muscle?

Studies suggest Follistatin 344 is a peptide that is believed to inhibit the activity of myostatin, a protein that regulates muscle growth. Follistatin 344 is a synthetic variant of endogenous Follistatin. The protein in question is composed of a total of 323 amino acids and is classified as a glycoprotein due to the presence of

Losing grip strength, slowing down may be dementia warning signs - Vimarsana News

Losing grip strength, slowing down may be dementia warning signs

The researchers used grip strength and Timed Up and Go (TUG) as measures of muscle strength

Loss of Muscle Strength May be a Dementia Warning Sign - Vimarsana News

Loss of Muscle Strength May be a Dementia Warning Sign

Measuring muscle function as part of dementia screening is useful in identifying high-risk individuals who might benefit from primary prevention programs.

Slowing down in your old age? It may be a dem - Vimarsana News

Slowing down in your old age? It may be a dem

It’s generally accepted we will lose muscle strength and slow down as we age, making it more difficult to perform simple tasks such as getting up, walking and sitting down. But new Edith Cowan University (ECU) research indicates this could also be a signal for another sinister health concern of ageing: late-life dementia.

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan - Vimarsana News

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

- Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3 patients away from dosing its final patient in its first Phase 2 clinical trial of lead drug candidate... | April 12, 2023